SF3A3 directly binds to protein arginine methyltransferase 5 (PRMT5), and the degradation of SF3A3 weakens the formation of the SF3A3/PRMT5 complex, enhances the expression level of MDM4-S, and further activates downstream p53 signaling to inhibit the malignancy of NSCLC [147]. The gene discussed is PRMT5; the disease is non-small cell lung carcinoma.